Clario’s Post

Platform designs can accelerate development and improve understanding of patient populations, but there are several factors to get right before a master platform can be successful across the full study lifecycle – from defining study operations and infrastructure, to adjusting to dynamic needs. Download our insight brief to learn more. https://bit.ly/4adqxlm #oncology #clinicaltrials #earlyphaseoncology

Join Caidya this Friday at 11am EST/4pm GMT for an insightful webinar on the Strategic Implications of Oncology Clinical Trial Design in Early-Phase Studies. Hosted by Caidya and Xtalks, this webinar will provide valuable insights into the latest trends and strategies in clinical trial design. Don't miss this discussion on novel trial designs, the importance of dose-finding studies in early-phase trials to later registrational trials, and more. Register now: https://lnkd.in/dXWiibJD #webinar #clinicaltrialdesign #oncologyresearch

Platform designs can accelerate development and improve understanding of patient populations, but there are several factors to get right before a master platform can be successful across the full study lifecycle – from defining study operations and infrastructure, to adjusting to dynamic needs. Download our insight brief to learn more. https://bit.ly/3WCo7su #oncology #clinicaltrials #earlyphaseoncology

This will be a great opportunity to learn about Translational Drug Development (TD2)'s expansion into Europe and our commitment to accelerating #CancerTherapeuticDevelopment from #BenchToBedside. #TD2 #cancertherapeutic #clinicaltrial #clinicaldevelopment #regulatoryconsulting #TheTD2Difference

Platform designs can accelerate development and improve understanding of patient populations, but there are several factors to get right before a master platform can be successful across the full study lifecycle – from defining study operations and infrastructure, to adjusting to dynamic needs. Download our insight brief to learn more. https://bit.ly/3UDP6kS #oncology #clinicaltrials #earlyphaseoncology

Platform designs can accelerate development and improve understanding of patient populations, but there are several factors to get right before a master platform can be successful across the full study lifecycle – from defining study operations and infrastructure, to adjusting to dynamic needs. Download our insight brief to learn more. https://bit.ly/3OkHj9c #oncology #clinicaltrials #earlyphaseoncology

The integration of efficacy, safety, and quality of life data maximizes the overall value of a clinical trial, enabling an inclusive assessment of benefits and risks, and ensuring that novel cancer therapies meet patients’ needs holistically. That’s the argument made in an article by Clario's Chief Medical Officer, Todd Rudo, M.D.; Chief Science and Regulatory Advisor-Cardiology, Robert B. Kleiman MD, M.D.; and Director of eCOA Science, Kelly Dumais, Ph. D. Check out the article for their guidance on how to design oncology trials for a comprehensive understanding of the therapeutic impact and patient quality of life in the development of new oncology drugs. ➡️ https://hubs.li/Q02GbGmt0 #clinicaltrials #oncology #drugdevelopment

The European Society for Medical Oncology, or ESMO, held its 2023 global conference in late October. Discover four key takeaways from this year’s ESMO Congress and what they mean for the future of oncology, from Anne Dhulesia and Sean Dyson https://bit.ly/3R5vZyr #LEKLifeSciences #lifesciences #oncology #ESMO23

The integration of efficacy, safety, and quality of life data maximizes the overall value of a clinical trial, enabling an inclusive assessment of benefits and risks, and ensuring that novel cancer therapies meet patients’ needs holistically. That’s the argument made in an article by Clario's Chief Medical Officer, Todd Rudo, M.D.; Chief Science and Regulatory Advisor-Cardiology, Robert B. Kleiman MD, M.D.; and Director of eCOA Science, Kelly Dumais, Ph. D. Check out the article for their guidance on how to design oncology trials for a comprehensive understanding of the therapeutic impact and patient quality of life in the development of new oncology drugs. ➡️ https://lnkd.in/gr_Fhm_r #clinicaltrials #oncology #drugdevelopment

From sponsors to CROs, we believe that everyone involved in clinical trials has a responsibility to increase access for historically underserved populations. In our insight brief, IQVIA Biotech’s Gerhard du Toit and IQVIA’s Murray Aitken consider the steps that every stakeholder can take toward improving D&I. Download now. https://bit.ly/427qvs5 #oncology #clinicaltrials #earlyphaseoncology